Danaher Corporation

Valuation Analysis

About the Company

Danaher Corporation en bref

Danaher Corporation (DHR) is currently trading at 154,64 € with a market capitalization of 109,5 Md €. The trailing P/E ratio stands at 34.31x, with a forward P/E of 19.18x. The 52-week range spans from 140,29 € to 211,66 €; the current price is 26.9% below the yearly high. Year-over-year revenue growth stands at +3.7%. The net profit margin stands at 14.89%.

💰 Dividende

Danaher Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

23 analystes évaluent Danaher Corporation (DHR) au consensus : Achat Fort. L'objectif de cours moyen est de 211,27 €, soit un potentiel de +36.62% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 174,35 € à 270,25 €.

Danaher Corporation : la thèse d'investissement en détail

Danaher Corporation (DHR) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

The combination of a 58.99% gross margin and 22.94% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Wall Street consensus sits at Strong Buy with an average price target implying roughly 36.62% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 3.7%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The PEG ratio at 1.16 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The forward P/E of 19.18x is meaningfully below the trailing 34.31x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 36.62% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Danaher Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.